Stripe hit $106.7B valuation and first-ever profitability in 2024, processing $1.4T in payments. Yet founders say "no near-term IPO." Why the most anticipated tech IPO keeps delaying—and what it means for 150+ zombie unicorns trapped behind it.
Databricks has emerged as the most valuable private technology company globally, reaching a $100+ billion valuation in September 2025 while generating over $4 billion in revenue with remarkable 50%+ growth. The company is strategically delaying its IPO until market conditions optimize, targeting 2025-2026, despite being operationally ready with positive free
China's leading robotics manufacturer Unitree is officially preparing for an IPO on Shanghai's STAR Market by Q4 2025, targeting a $7 billion valuation that would mark the world's first major humanoid robotics public listing. The company, which has dominated global quadruped robot sales with
The recent controversy surrounding DeepSeek, the Chinese AI startup, and its alleged use of OpenAI-generated outputs to train its models has sparked heated debates in the tech and AI communities. OpenAI and Microsoft are investigating whether DeepSeek improperly obtained data from OpenAI's API, potentially violating terms of service.
Leading pharmaceutical companies and academic researchers have made significant strides in enhancing existing treatments and discovering new therapeutic options.
Voyager Therapeutics, a clinical-stage biotechnology company, is making remarkable strides in the field of neurogenetic medicine. Specializing in gene therapy to address neurological diseases, Voyager is on a mission to leverage human genetics to modify the course of these debilitating conditions and ultimately provide cures. The company’s innovative approaches
As the world becomes increasingly health-conscious, the demand for sugar alternatives has skyrocketed. This surge is not just a boon for our waistlines but also a golden opportunity for investors looking to capitalize on the growing market. Let's delve into the trade-offs and health aspects of popular sugar
a German value stock with a dividend.
KCGI merger, Dieter, Recession Proof sales, $40k per vehicle in government incentives, and insane under-valuation compared to peers all make this Arrival story extremely juicy for us.
If you have been an investor in Arrival and owned Arrival stock within the last year, chances are, you lost a lot of money. Is it your fault? We are inclined to say no. On the contrary, we still believe it might be the EV bet of the century.
